Waldenström macroglobulinemia: What a hematologist needs to know
- 1 September 2015
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 29 (5), 301-319
- https://doi.org/10.1016/j.blre.2015.03.001
Abstract
No abstract availableKeywords
This publication has 137 references indexed in Scilit:
- Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid MalignanciesActa Haematologica, 2012
- Temporal and geographic variations of Waldenstrom macroglobulinemia incidenceCancer, 2011
- MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterpartsBlood Cancer Journal, 2011
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's MacroglobulinemiaClinical Cancer Research, 2010
- Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trialBritish Journal of Haematology, 2009
- CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemiaBlood, 2008
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Genomewide Linkage Screen for Waldenström Macroglobulinemia Susceptibility Loci in High-Risk FamiliesAmerican Journal of Human Genetics, 2006
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003